Patient Profile: Type 2 diabetic, A1c of 12.9
Medications:
- Ozempic™
- Rosuvastatin
- Olmesartan (discontinued)
- Insulin (discontinued)
Northwind Actions: Motivation and health coaching created lasting behavior change and clinical improvement as well as discontinuation of multiple therapies
Measures Taken:
- Focused on nutrition changes and motivational triggers
Clinical Results:
- A1c trend: 6.9% Reduction in 6 months
- Upon program enrollment in December 2023, patient’s hemoglobin A1c was 12.9%. Over the course of his engagement and work with the Northwind team, he achieved an A1c of 6.0% in June 2024 and has maintained his clinical outcomes through ongoing commitment to his health.
- Insulin and BP med discontinued due to improved control